Fixed Price IPO | ₹25 Cr | Listed at NSE SME | Fri, Mar 31, 2023 - Wed, Apr 5, 2023
Infinium Pharmachem IPO is a fixed price issue of ₹25.25 crores. The issue is entirely a fresh issue of 0.19 crore shares of ₹25.25 crore.
Infinium Pharmachem IPO bidding started from Mar 31, 2023 and ended on Apr 5, 2023. The allotment for Infinium Pharmachem IPO was finalized on Apr 11, 2023. The shares got listed on NSE SME on Apr 17, 2023.
Infinium Pharmachem IPO price is ₹135 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹1,35,000 (1000 shares) (based on upper price). The minimum lot size for investment in HNI is 2 lots (2,000 shares), amounting to ₹2,70,000.
The issue includes a reservation of up to 41,000 shares for employees offered at a discount of ₹13.50 to the issue price.
Swastika Investmart Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Swastika Investmart Ltd..
Refer to Infinium Pharmachem IPO RHP for detailed Information.
IPO Open
Fri, Mar 31, 2023
IPO Close
Wed, Apr 5, 2023
Issue Price
₹135 per share
Market Cap (Pre-IPO)
₹93.93 Cr
| IPO Date | 31 Mar to 5 Apr, 2023 |
| Listed on | Mon, Apr 17, 2023 |
| Face Value | ₹10 per share |
| Issue Price | ₹135 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Fixed Price IPO |
| Listing At | NSE SME |
| Employee Discount | ₹13.50 |
| Total Issue Size | 18,75,000 shares (agg. up to ₹25 Cr) |
| Reserved for Market Maker | 94,000 shares Swastika Investmart Ltd. (agg. up to ₹1 Cr) |
| Fresh Issue (Ex Market Maker) | 17,81,000 shares (agg. up to ₹24 Cr) |
| Net Offered to Public | 17,81,000 shares (agg. up to ₹24 Cr) |
| Share Holding Pre Issue | 50,83,060 shares |
| Share Holding Post Issue | 69,58,060 shares |
| NSE Symbol | INFINIUM |
| ISIN | INE0MRE01011 |
Infinium Pharmachem IPO comprises a total issue size of 18,75,000 shares. The net offer to the public is 17,40,000 shares, after excluding 94,000 shares allotted on a firm basis and 41,000 shares under a preferential allotment. Of the Net offer 8,70,000 (50.00%) allocated to NII 8,70,000 (50.00%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| NII (HNI) Shares Offered | 8,70,000 | 50.00% | 46.40% |
| Retail Shares Offered | 8,70,000 | 50.00% | 46.40% |
| Preferential Reservations | |||
| Employee Shares Offered | 41,000 | 2.19% | |
| Firm Reservations | |||
| Market Maker Shares Offered | 94,000 | 5.01% | |
| Total Shares Offered | 18,75,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 1,000 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹1,35,000 |
| Retail (Max) | 1 | 1,000 | ₹1,35,000 |
| HNI (Min) | 2 | 2,000 | ₹2,70,000 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only NII | Above Rs 2 Lakhs | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 2003, Infinium Pharmachem Limited manufactures & supplies Iodine Derivatives, APIs, and Iodination reaction-based bulk drugs.
The company offers R & D services and commercial scale manufacturing and packaging for Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals & other chemical industries.
Infinium Pharmachem's manufacturing plant is located in Gujarat - INDIA, which spans across 4100 Sq. Mtr. Plot area. The facility is FDA certified & GMP compliant with capabilities of producing complex Iodine Derivatives.
The company serves to over 15+ countries across the globe and has over 200+ Iodine Derivatives and 7+ APIs.
| Period Ended | 30 Sep 2022 | 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 |
|---|---|---|---|---|
| Assets | 70.76 | 59.00 | 34.18 | 22.45 |
| Total Income | 79.85 | 100.05 | 71.15 | 39.42 |
| Profit After Tax | 5.51 | 6.11 | 2.72 | 0.93 |
| NET Worth | 18.56 | 13.10 | 7.02 | 4.25 |
| Reserves and Surplus | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Borrowing | 16.15 | 13.85 | 5.79 | 5.66 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Marketing and Branding Expenses (including Registration in Reach - Europe, other marketing expenses) | 1.13 |
| 2 | Repayment of some of Existing Loans; | 3.92 |
| 3 | Expansion of Existing Unit | 5.05 |
| 4 | To Meet Incremental Working Capital Requirements; | 10.10 |
| 5 | General Corporate Purpose | 4.43 |
| KPI | Mar 31, 2022 |
|---|---|
| ROE | 43.85 |
| ROCE | 72 |
| Debt/Equity | 2.91 |
| RoNW | 46.61 |
| PAT Margin | 6.16% |
| EBITDA Margin | 11.06% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 54.13 | |
| P/E (x) | 7.83 | |
| Promoter Holding | 100% | 73.05% |
| Market Cap | ₹93.93 Cr. |
The Infinium Pharmachem IPO is subscribed 1.92 times on April 5, 2023 7:30:00 PM (Day 3). The public issue subscribed 2.00 times in the retail category, [.] times in the QIB category, and 1.94 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (x) | Shares Offered | Shares bid for |
|---|---|---|---|
| NII* | 1.94 | 8,70,000 | 16,86,000 |
| Retail | 2.00 | 8,70,000 | 17,42,000 |
| Employee | 1.29 | 41,000 | 53,000 |
| Total | 1.92 | 17,81,000 | 34,28,000 |
Total Applications: 1,742
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Manger Fees including Underwriting Commission | 0.25 |
| 2 | Fees Payable to Registrar to the Issue | 0.01 |
| 3 | Fees Payable Advertising, Marketing Expenses and Printing Expenses | 0.25 |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | 0.04 |
| 5 | Fees payable to Peer Review Auditor, Legal Advisor and Other Professional | 0.03 |
| 6 | Fees Payable to Market Maker (for Two Years). | 0.05 |
| 7 | Escrow Bank Fees | 0.00 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹135.00 |
| Open | ₹141.50 |
| Low | ₹141.50 |
| High | ₹148.55 |
| Last Trade | ₹147.80 |
Lead Manager Reports
Infinium Pharmachem IPO is a SME IPO of 18,75,000 equity shares of the face value of ₹10 aggregating up to ₹25 Crores. The issue is priced at ₹135 per share. The minimum order quantity is 1000.
The IPO opens on Fri, Mar 31, 2023, and closes on Wed, Apr 5, 2023.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Infinium Pharmachem IPO using UPI as a payment gateway. Zerodha customers can apply in Infinium Pharmachem IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Infinium Pharmachem IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Infinium Pharmachem IPO opens on Fri, Mar 31, 2023 and closes on Wed, Apr 5, 2023.
Infinium Pharmachem IPO lot size is 1000, and the minimum amount required for application is ₹1,35,000.
You can apply in Infinium Pharmachem IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Infinium Pharmachem IPO will be done on Tuesday, April 11, 2023, and the allotted shares will be credited to your demat account by Thu, Apr 13, 2023. Check the Infinium Pharmachem IPO allotment status.
The Infinium Pharmachem IPO listing date is on Mon, Apr 17, 2023.
